OraVax, Pasteur Merieux, Peptide Therapeutics deal

PTE completed its acquistion of ORVX for $3 million in cash and a $17 million purchase of 10 million new PTE shares (see BioCentury, Feb 1). The acquisition triggered the exercise of an option by Past...